New gene therapy aims to restore saliva in cancer survivors
NCT ID NCT02446249
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gene therapy designed to help people with dry mouth after radiation for head and neck cancer. The treatment delivers a gene into one saliva gland to help it produce more saliva. The trial includes 17 adults and focuses on safety, with follow-up over three years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION-INDUCED XEROSTOMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single gene therapy dose restore saliva flow years after radiation?
- New hope for cancer patients: preventing dry mouth before it starts
- Stem cells offer hope for cancer survivors with chronic dry mouth
- Zapping the brain to kick the habit: rTMS tested for smoking relapse
- Acupuncture offers hope for cancer survivors suffering from chronic dry mouth
- Mouth feel may explain why cancer patients stop eating